每经记者｜甄素静 每经编辑｜段炼 廖丹 一个月前曾因"脑机接口"合作信息披露不准确而被上交所予以监管警示的亚辉龙（SH688575，股价14.45元，市值83亿元）如今又被证监会立案。 2月6日晚间，亚辉龙发布公告称，公司于当日收到中国证监会下发的《立案告知书》，因公司涉嫌信息披露违法违规，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，证监会决定对公司予以立案。 同日，证监会官网披露，2026年1月7日，亚辉龙披露签署战略合作框架协议的公告，涉嫌误导性陈述。"近日，我会已对亚辉龙立案调查。下一步，将在 全面调查的基础上依法处理，切实维护市场健康发展。" 针对此次证监会立案，亚辉龙表示，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关工作，并严格按照相关 法律法规和监管要求及时履行信息披露义务，并提醒投资者注意投资风险。 对于此次立案调查，亚辉龙方面表示，目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关工作，并严格按照相 关法律法规和监管要求及时履行信息披露义务。 《每日经济新闻》记者注意到，这一消息距离亚辉龙披露202 ...

据悉，2026年1月7日，深圳市亚辉龙生物科技股份有限公司（简称亚辉龙）披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙 立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 同日，亚辉龙亦发布关于收到中国证券监督管理委员会立案告知书的公告。 2月26日，证监会官网发布公告称，对亚辉龙公告涉嫌误导性陈述立案调查。 亚辉龙表示，公司于2026年2月6日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》，因涉嫌信息披露违法违规，根据《中华 人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司予以立案。 亚辉龙此次被查与此前披露的公告相关。1月6日晚，亚辉龙发布公告称，于近日与深圳脑机星链科技有限公司（以下简称："脑机星链"）签署了《战略合作 框架协议》。双方将通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广。亚辉龙同时强调，本次签署的 协议为意向性约定，不涉及具体金额，无需提交公司董事会、股东大会审议。 同日，上交所就紧急向亚辉龙发送了问询函，并对亚辉龙及有关责任人予以监管警示的决定。 ...

据中国证监会2月6日消息， 近日，证监会对深圳市亚辉龙生物科技股份有限公司（以下简称"亚辉龙"） 立案调查。 据悉， 1月7日， 亚 辉龙 披露签署战略合作框架协议的公告，涉嫌误导性陈述。 证监会表示，下一步，将在全面调查的基础上依法处理，切实维护市场健康发 展。 同日，亚辉龙披露公告称 ，于2月6日收到中国证监会的《立案告知书》，因涉嫌信息披露违法违规，根据《 中华人民共和国 证券法》《 中华人民共和国 行政处罚法》等法律法规，中国证监会决定对公司予以立案。目前公司各项经营活动和业务均正常开展。立案调查期间， 公司将积极配合中国证监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 该公告披露后引发市场关注，上交所火速下发问询函。上交所要求公司补充说明情况，包括脑机星链主要技术路线、主要产品类型、应用 领域、产品所处研发或商业化状态；双方产品在应用领域、客户、渠道等方面的协同性；双方未来签署后续推广协议的预计时间安排；开 展合作研发的具体领域、合作方式、公司预计投入金额；结合公司业绩和资金状况，说明开展相关合作对公司现有主营业务的具体影响 等。 在监管督促下，亚辉龙1月6日晚又发布补充公告 ...

2月26日，证监会官网发布公告称，对亚辉龙公告涉嫌误导性陈述立案调查。 据悉，2026年1月7日，深圳市亚辉龙生物科技股份有限公司（简称亚辉龙）披露签署战略合作框架协议 的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处 理，切实维护市场健康发展。 同日，亚辉龙亦发布关于收到中国证券监督管理委员会立案告知书的公告。 亚辉龙表示，公司于2026年2月6日收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《立 案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚 法》等法律法规，中国证监会决定对公司予以立案。 亚辉龙此次被查与此前披露的公告相关。1月6日晚，亚辉龙发布公告称，于近日与深圳脑机星链科技有 限公司（以下简称："脑机星链"）签署了《战略合作框架协议》。双方将通过整合脑机接口技术与临床 和市场资源，共同开发脑机接口相关在研产品及推进后续市场拓展及推广。亚辉龙同时强调，本次签署 的协议为意向性约定，不涉及具体金额，无需提交公司董事会、股东大会审议。 同日，上交所就紧急向亚辉龙发送了问询函，并对亚辉龙及有关责任人予以监管警示的 ...

Core Viewpoint - Rongbai Technology is facing administrative penalties from the Ningbo Securities Regulatory Bureau due to misleading statements in a major contract announcement with CATL, which involved a projected supply of 3.05 million tons of lithium iron phosphate cathode materials worth over 120 billion yuan [2][4][19]. Group 1: Contract Announcement Issues - The contract announcement failed to accurately reflect the actual terms, including the total sales amount, which was described as an estimate with inherent uncertainties [6][18]. - The agreement stipulated that the procurement volume would be no less than 70% of the forecasted 3.05 million tons, contingent on subsequent contracts [6][18]. - The announcement indicated supply from Q1 2026 to 2031, while the contract's validity extends only until December 31, 2030 [6][18]. - The requirement for Rongbai Technology to meet comprehensive competitiveness criteria was not disclosed in the announcement [6][18]. Group 2: Regulatory Actions and Penalties - The Ningbo Securities Regulatory Bureau plans to issue warnings and fines to Rongbai Technology and its executives, including 4.5 million yuan for the chairman, 3 million yuan for the secretary, and 2 million yuan for the general manager [7][19]. - The actions are based on violations of the Securities Law of the People's Republic of China, specifically regarding misleading statements [7][19]. - The company asserts that the violations do not trigger other risk warnings or mandatory delisting scenarios under the Shanghai Stock Exchange's regulations [8][20]. Group 3: Broader Regulatory Context - The China Securities Regulatory Commission has demonstrated a strong enforcement stance against market misconduct, indicating a "zero tolerance" policy towards violations [9][21]. - Other companies, such as Yahui Long and Tiansheng New Materials, are also under investigation for similar disclosure violations, highlighting a trend of increased regulatory scrutiny in the market [10][22].

据中国证监会2月6日消息，近日，证监会对深圳市亚辉龙生物科技股份有限公司(以下简称"亚辉龙")立案调查。据悉，1月7日，亚辉龙披露签署战略合作 框架协议的公告，涉嫌误导性陈述。证监会表示，下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 此前，在"脑机接口"热潮之下，亚辉龙因信披"蹭热点"被上海证券交易所(以下简称"上交所")监管警示。 同日，亚辉龙披露公告称，于2月6日收到中国证监会的《立案告知书》，因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会决定对公司予以立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司将积极配合中国证监会的相关 工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 从二级市场表现看，1月6日，亚辉龙股价上涨6.52%、成交量较前一个交易日增长299%。 1月6日晚间，亚辉龙发布《关于自愿披露签署战略合作框架协议的公告》。根据公告，亚辉龙宣布与深圳脑机星链科技有限公司(以下简称"脑机星链")签 署战略合作框架协议，双方共同达成战略合作，通过整合脑机接口技术与临床和市场资源，共同开发脑机接口相关在研 ...

智通财经记者 | 李科文 智通财经编辑 | 谢欣 脑机接口已成上海未来产业重点发展方向。 日前，上海"十五五"规划明确以先进制造业为骨干，构建"2+3+6+6"现代化产业体系，打造世界级高端 产业集群。其中，在六大新兴支柱产业集群，未来健康领域提及加强脑机接口的敏捷布局，加快培育成 势。 2026年上海两会期间，市政协委员、复旦大学附属华山医院神经外科副主任吴劲松建议，当前正处于脑 机接口技术从实验室走向产业化的关键期，上海必须把握机遇，加快打造世界脑机接口中心城市。 非侵入式因操作简便、安全性高，已在消费级及部分医疗场景中应用，但受颅骨阻隔影响，信号采集精 度有限，短期内难以支撑重症患者的高要求康复。侵入式与半侵入式虽然面临技术与伦理挑战，却已成 为医疗康复领域的核心突破方向。 上海市卫生和健康发展研究中心主任金春林向智通财经表示，"未来健康"定位以将脑机接口定义为超越 传统医疗器械范畴，视作生命科学、人工智能与先进制造交叉的前沿方向。战略信号明确，强政策支持 上海抢占全球科技竞争制高点。 他认为，"敏捷布局"的重点在于更灵活、更快速地响应技术迭代与场景拓展，通过机制创新（如快速审 批通道等）加速技术转化， ...

Core Viewpoint - The company YHLO (SH688575) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, following a previous warning from the Shanghai Stock Exchange regarding inaccurate disclosures related to a strategic cooperation agreement [1][3]. Group 1: Regulatory Actions - YHLO received a notice from the CSRC on February 6, indicating that the company is under investigation for alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [1][3]. - The investigation stems from a January 7 announcement regarding a strategic cooperation framework agreement, which was found to contain misleading statements [1][3]. - The Shanghai Stock Exchange had previously issued a regulatory warning to YHLO's then-Secretary of the Board, highlighting issues of inaccurate and incomplete information disclosure [3][4]. Group 2: Financial Performance - YHLO's 2025 earnings forecast indicates a significant decline, with expected net profit attributable to shareholders dropping over 90% compared to the previous year, projecting between 20 million to 30 million yuan, down from approximately 300 million yuan in 2024 [5][6]. - The company attributes the decline in performance to industry policy impacts, resulting in reduced domestic market demand and lower revenue and gross margin [6][7]. - Additionally, YHLO reported losses from its trading financial assets, specifically from its holdings in Cloud Health Group Limited, and plans to recognize impairment losses on various assets [6][7]. Group 3: Business Operations - Despite domestic challenges, YHLO has achieved some success in overseas markets, with stable growth in international marketing and ongoing efforts in product development and market access [7]. - The company has completed the highest level (Class D) IVDR CE certification for its full range of preoperative chemiluminescence testing reagents, indicating progress in its product offerings [7].

Group 1: Company Overview - Chengdu Sailano Medical Technology Co., Ltd. (Sailano) has officially signed to establish its headquarters in Chengdu Tianfu International Bio-City, focusing on the field of structural heart disease [1][3] - Sailano aims to become a unicorn in the field of pan-cardiac disease medical devices, with a global innovation capability and a forward-looking vision [3] - The company holds 21 invention patents and 19 utility model patents, showcasing its strong intellectual property portfolio [3] Group 2: Research and Development - Sailano plans to build a headquarters, R&D center, and production base in the bio-city to systematically conduct research, production, and sales of medical devices for structural heart disease [3] - The company has established close clinical trial cooperation with top cardiac centers in China, creating a collaborative innovation system from clinical needs to technology transfer [3] - Sailano's product pipeline targets the core area of interventional treatment for structural heart disease, with several in-development products possessing "international advanced" technical advantages [3] Group 3: Clinical Applications and Collaborations - The company will leverage its existing clinical cooperation network and R&D platform to accelerate clinical research, registration, and industrialization of core products after settling in the bio-city [3] - The high-frequency skin ultrasound technology developed by Tianfu Jin Cheng Laboratory has entered clinical validation, providing a new tool for skin disease diagnosis and treatment evaluation [6][10] - The technology aims to enhance the precision of skin disease diagnosis by offering non-invasive, real-time imaging capabilities [10] Group 4: Industry Developments - Chengdu Biomedicine has seen multiple advancements in various subfields, including the structural heart disease sector [4] - Chengdu Baili Tianheng Pharmaceutical Co., Ltd. has been recognized in the "2025 Hurun China 500" list, ranking 86th with a value of 153 billion yuan, an increase of 79.5 billion yuan [12] - Baili Tianheng is developing innovative drugs in the tumor macromolecule treatment field and has received multiple breakthrough therapy designations from regulatory agencies [12]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. for allegedly misleading statements in their announcements regarding a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [1] Group 1: Company Actions and Announcements - On January 6, Yahui Long announced a strategic cooperation agreement with Brain Machine Star Chain, claiming collaboration in product development, market promotion, and equity investment, highlighting the latter's focus on artificial intelligence and various technology paths [1] - Following regulatory pressure, Yahui Long issued a supplementary announcement clarifying that Brain Machine Star Chain's current research products only involve non-invasive technology and that some products are still in early research or preclinical stages [1] Group 2: Regulatory Responses - On January 7, the Shanghai Stock Exchange issued a regulatory warning to Yahui Long and related responsible parties, emphasizing the need for accurate and complete information disclosure, especially regarding the hot market concept of "brain-machine interfaces" [2] - The announcement from Yahui Long contained inconsistent statements about the technology paths of Brain Machine Star Chain and failed to adequately address key investor concerns regarding cooperation feasibility and associated risks [2] Group 3: Industry Context - Multiple listed companies have faced regulatory warnings and investigations this year for allegedly misleading statements related to market trends, including Ningbo Rongbai New Energy Technology Co., Ltd. and Ningbo Tianpu Rubber Technology Co., Ltd., indicating a broader trend of scrutiny in the industry [3] - The regulatory environment is tightening as the exchanges have taken action against several companies for "hitching a ride" on market hotspots, highlighting the importance of accurate disclosures in maintaining market integrity [3]